Tan M H, Gordon M, Lebwohl O, George J, Lebwohl M G
Department of Dermatology, Box 1047, The Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Arch Dermatol. 2001 Jul;137(7):930-3.
Infliximab is an anti-tumor necrosis factor alpha monoclonal antibody IgG effective in the treatment and maintenance of remission of active refractory Crohn disease and associated draining enterocutaneous fistulae. Multiple infusions of infliximab show promising results in patients with rheumatoid arthritis. Currently, there is limited clinical experience with infliximab, and no published reports exist on its use in cutaneous disorders.
We describe 2 patients with Crohn disease and pyoderma gangrenosum and 1 patient with Crohn disease and psoriasis who were treated with infliximab for recalcitrant Crohn fistulae, with concurrent improvement in their skin diseases.
These cases suggest that infliximab, a promising therapeutic agent for refractory Crohn disease and fistulae, may also be effective in the treatment of pyoderma gangrenosum and psoriasis associated with Crohn disease.
英夫利昔单抗是一种抗肿瘤坏死因子α单克隆抗体IgG，对治疗和维持活动性难治性克罗恩病及相关引流性肠皮肤瘘的缓解有效。多次输注英夫利昔单抗对类风湿关节炎患者显示出有前景的结果。目前，英夫利昔单抗的临床经验有限，且尚无关于其用于皮肤疾病的发表报告。
我们描述了2例患有克罗恩病和坏疽性脓皮病的患者以及1例患有克罗恩病和银屑病的患者，他们因顽固性克罗恩瘘接受英夫利昔单抗治疗，同时其皮肤病也得到改善。
这些病例表明，英夫利昔单抗作为一种对难治性克罗恩病和瘘有前景的治疗药物，可能对治疗与克罗恩病相关的坏疽性脓皮病和银屑病也有效。
Zotero 插件